Welcome to our dedicated page for Stereotaxis Ord news (Ticker: STXS), a resource for investors and traders seeking the latest updates and insights on Stereotaxis Ord stock.
Stereotaxis, Inc. develops robotic technologies for minimally invasive endovascular intervention, with recurring news centered on electrophysiology and arrhythmia treatment. Company updates cover the MAGiC™ Magnetic Interventional Ablation Catheter, MAGiC Sweep high density mapping catheter, Genesis and GenesisX robotic magnetic navigation systems, and related clinical use in complex heart-rhythm procedures.
News also includes FDA and international regulatory clearances or approvals, hospital robotic heart-arrhythmia program launches, commercialization of cath-lab technologies such as Synchrony™ and SynX™, manufacturing and product-pipeline progress, material agreements, capital-structure updates, and periodic operating and financial results.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular interventions, will release its Q1 2023 financial results on May 9, 2023, before U.S. markets open. A conference call is scheduled for the same day at 10 a.m. EST to discuss the results and corporate updates. Investors can access the call by dialing 800-715-9871 (US) or 1-646-307-1963 (International), using pass code 8054202. A replay of the call will be available for one month after the live event. Stereotaxis aims to enhance patient care through its robotic solutions, having served over 100,000 patients across various regions. This announcement emphasizes the company's commitment to transparency and engagement with its shareholders, as it prepares to disclose vital financial information.
Stereotaxis (NYSE: STXS) announced that over 1,000 cardiac arrhythmia patients have been treated using the Genesis Robotic Magnetic Navigation (RMN) system since its introduction in late 2020. This advanced technology has been implemented at eight hospitals globally, including Banner University Medical Center and the National Institute of Cardiology in Poland. The Genesis RMN system enhances robotic precision and safety for cardiac ablation procedures, benefiting patients with complex cardiac diseases. With nearly two dozen robotic systems ordered, demand for the technology is growing. Stereotaxis continues to focus on providing innovative robotic solutions for minimally invasive interventions, having treated over 100,000 patients to date.
Stereotaxis (NYSE: STXS) has launched a new robotic electrophysiology program at Broward Health Medical Center in Fort Lauderdale, Florida, marking a significant advancement in cardiac care. The facility is the first in Florida and among the first in the U.S. to utilize the Genesis Robotic Magnetic Navigation System for treating complex heart rhythm disorders. This innovative technology aims to enhance patient safety and precision during cardiac ablation procedures, addressing the needs of millions affected by arrhythmias. The collaboration highlights Stereotaxis's commitment to advancing cardiac services and improving patient outcomes.
Stereotaxis (STXS) reported its financial results for Q4 and FY 2022, revealing a revenue decline to $7.3 million in Q4 from $8.2 million in Q4 2021. Full-year revenue dropped to $28.1 million from $35.0 million, attributed to hospital construction delays affecting system placements. The company recorded a net loss of $4.2 million in Q4 and an adjusted net loss of $7.8 million for the year. Despite these challenges, Stereotaxis aims for double-digit revenue growth in 2023, driven by a strong backlog of $14.8 million and expected regulatory approvals for new product innovations.